HOLLY LOFTON: Open Payments
NPI 1104010511 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$171,327 in 198 payments from 10 companies in 2025. Trend: 2023 $60,258 · 2024 $183,965 · 2025 $171,327
Speaker / faculty: $117,929Consulting: $37,891Travel & lodging: $10,555Food & beverage: $4,953
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 96 | $92,509 |
| Novo Nordisk Inc | 68 | $63,289 |
| Eli Lilly and Company | 8 | $5,500 |
| Currax Pharmaceuticals LLC | 9 | $5,482 |
| ABBVIE INC. | 1 | $2,250 |
| Madrigal Pharmaceuticals | 5 | $1,885 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $180 |
| Intra-Sana Laboratories | 1 | $114 |
| Corcept Therapeutics | 3 | $65 |
| Perspectum Diagnostics Ltd | 1 | $53 |
Products named: ZEPBOUND, Wegovy, Saxenda, CONTRAVE, IMBRUVICA, REZDIFFRA, MOUNJARO, JARDIANCE.
Industry payments across NY — which companies pay providers there.
